Haemophilia B (F9, factor IX deficiency) OMIM 306900
In Haemophilia B (F9, OMIM 306900), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: supply). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.
The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.3986, γ 1.2627, spinodal 0.5461). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.
The emergence switch
The switch for Haemophilia B is an R19 double-well emerged from the real proximal-promoter DNA of F9. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.
emergent axis
↓ DOWN [F]
healthy branch
ON
lesion
LOF_null
γ (stiffness)
1.2627
barrier
0.3986
spinodal
0.5461
s_on / s_off
1.1237 / -1.1237
fragility
0.96
corrective polarity
supply
forced direction
raise s toward ON branch
Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically plausible (barrier 0.3986 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.
The derived corrective lever
The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).
Mechanism. supply / restore the positive drive (replace-or-agonise the missing competence)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If supplying/agonising F9 (raising the switch drive) does NOT move the DOWN [F] switch toward the healthy branch in a F9-deficient model, the h-restore(supply) lever is refuted for this axis.
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual F9 allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.
Agents mapped onto the lever
✓ Agreement with established practice. The corrective direction derived here (raise s toward ON branch) independently matches an agent already in clinical use for this disease: AAV F9 gene replacement (etranacogene dezaparvovec; also fidanacogene elaparvovec); factor IX protein replacement (recombinant / plasma-derived; extended-half-life Fc / albumin / PEG fusions). The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
agent (class)
dir.
status
phase
map
AAV F9 gene replacement (etranacogene dezaparvovec; also fidanacogene elaparvovec)
Nathwani 2011 NEJM 365:2357 and 2014 NEJM 371:1994 (AAV F9 first-in-human); etranacogene dezaparvovec (Hemgenix) FDA 2022 / EMA 2023 -- first approved haemophilia B gene therapy; fidanacogene elaparvovec (Beqvez) FDA 2024
increase
approved
4
✓ in use
factor IX protein replacement (recombinant / plasma-derived; extended-half-life Fc / albumin / PEG fusions)
recombinant factor IX (nonacog alfa) FDA 1997; extended-half-life rIX-FP (albutrepenonacog alfa) and rFIXFc (eftrenonacog alfa) approved
increase
approved
4
✓ in use
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Direction-only candidate leads (corpus join)
Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.
Mechanism. Infused to supply functional coagulation factor IX, replacing the product the null F9 gene cannot make. Direction: increase / restore the missing factor IX competence. Allele scope: agnostic -- replaces the downstream protein irrespective of the F9 variant. Pathway-specific to factor IX supply (mapped to haemophilia B). Factor concentrate is the established standard; the geometry's supply direction recovers it.
✓ This is a rediscovery. Factor IX replacement is the established standard of care for haemophilia B; the supply-direction logic recovered established practice.
Safety (qualitative; no magnitude). established replacement-factor class; inhibitor and hypersensitivity signals noted on label (qualitative; no magnitude)
Falsifier. If nonacog alfa (recombinant factor IX) (a pathway supply/increase agent) does NOT move the DOWN [F] switch toward the healthy branch in a F9-deficient model, the h-restore(supply) direction is refuted for nonacog alfa (recombinant factor IX) here.
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Evidence & provenance
What is reproduced vs. cited for this page.
element
grade
basis
R19 switch & cusp geometry (this page)
[V] verified
emerged from measured promoter γ of F9; deterministic, 2×sha256 identical
corrective direction
[F] forced
forced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads
[O] open
direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude
Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).